Delta-volume radiomics of induction chemotherapy to predict outcome of subsequent chemoradiotherapy for locally advanced hypopharyngeal cancer

Su, Che-Wei; Lee, Jehn-Chuan; Chang, Yi-Chun; Su, Nai-Wen; Lee, Pei‐Hsuan; Dai, Kun-Yao; Tai, Hung-Chi; Leu, Yi-Shing; Chen, Yu-Jen

doi:10.1177/03008916211039018

Cited by 3 publications

(2 citation statements)

References 45 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Loss of heterogeneity and improving homogeneity on the treatment/follow-up CT are known indicators of treatment response ( 20 ). Previously, delta GLZLM features have been shown to be useful in locally advanced hypopharyngeal cancers, and specifically, delta LGZE has been useful in head and neck cancers ( 21 , 22 ). Thus, overall, radiomic features and delta-radiomic features predict survival by providing quantitative information regarding tumor characteristics and the change in tumor characteristics on treatment.…”

Section: Discussionmentioning

confidence: 99%

Combination of clinical, radiomic, and “delta” radiomic features in survival prediction of metastatic gastroesophageal adenocarcinoma

Krishna,

Sertic,

Liu

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

ObjectivesTo identify combined clinical, radiomic, and delta-radiomic features in metastatic gastroesophageal adenocarcinomas (GEAs) that may predict survival outcomes.MethodsA total of 166 patients with metastatic GEAs on palliative chemotherapy with baseline and treatment/follow-up (8–12 weeks) contrast-enhanced CT were retrospectively identified. Demographic and clinical data were collected. Three-dimensional whole-lesional radiomic analysis was performed on the treatment/follow-up scans. “Delta” radiomic features were calculated based on the change in radiomic parameters compared to the baseline. The univariable analysis (UVA) Cox proportional hazards model was used to select clinical variables predictive of overall survival (OS) and progression-free survival (PFS) (p-value <0.05). The radiomic and “delta” features were then assessed in a multivariable analysis (MVA) Cox model in combination with clinical features identified on UVA. Features with a p-value <0.01 in the MVA models were selected to assess their pairwise correlation. Only non-highly correlated features (Pearson’s correlation coefficient <0.7) were included in the final model. Leave-one-out cross-validation method was used, and the 1-year area under the receiver operating characteristic curve (AUC) was calculated for PFS and OS.ResultsOf the 166 patients (median age of 59.8 years), 114 (69%) were male, 139 (84%) were non-Asian, and 147 (89%) had an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1. The median PFS and OS on treatment were 3.6 months (95% CI 2.86, 4.63) and 9 months (95% CI 7.49, 11.04), respectively. On UVA, the number of chemotherapy cycles and number of lesions at the end of treatment were associated with both PFS and OS (p < 0.001). ECOG status was associated with OS (p = 0.0063), but not PFS (p = 0.054). Of the delta-radiomic features, delta conventional HUmin, delta gray-level zone length matrix (GLZLM) GLNU, and delta GLZLM LGZE were incorporated into the model for PFS, and delta shape compacity was incorporated in the model for OS. Of the treatment/follow-up radiomic features, shape compacity and neighborhood gray-level dependence matrix (NGLDM) contrast were used in both models. The combined 1-year AUC (Kaplan–Meier estimator) was 0.82 and 0.81 for PFS and OS, respectively.ConclusionsA combination of clinical, radiomics, and delta-radiomic features may predict PFS and OS in GEAs with reasonable accuracy.

show abstract

Section: Discussionmentioning

confidence: 99%

Combination of clinical, radiomic, and “delta” radiomic features in survival prediction of metastatic gastroesophageal adenocarcinoma

Krishna,

Sertic,

Liu

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Delta radiomics represents the evolution of radiomic features along the time axis. Su et al [28 ▪ ] described a promising performance of delta radiomics between pretreatment and after IC in a cohort of patients with locally advanced hypopharyngeal cancer who subsequently underwent CRT.…”

Section: Delta Radiomicsmentioning

confidence: 99%

The added value of radiomics in determining patient responsiveness to laryngeal preservation strategies

Ravanelli,

Rondi,

Di Meo

et al. 2024

Current Opinion in Otolaryngology &Amp; Head &Amp; Neck Surgery

View full text Add to dashboard Cite

Purpose of review Laryngeal cancer (LC) is a highly aggressive malignancy of the head and neck and represents about 1–2% of cancer worldwide. Treatment strategies for LC aim both to complete cancer removal and to preserve laryngeal function or maximize larynx retention. Predicting with high precision response to induction chemotherapy (IC) is one of the main fields of research when considering LC, since this could guide treatment strategies in locally advanced LC. Recent findings Radiomics is a noninvasive method to extract quantitative data from the whole tumor using medical imaging. This signature could represent the underlying tumor heterogeneity and phenotype. During the last five years, some studies have highlighted the potential of radiomics in the pretreatment assessment of LC, in the prediction of response to IC, and in the early assessment of response to radiation therapy. Although these represent promising results, larger multicentric studies are demanded to validate the value of radiomics in this field. Summary The role of radiomics in laryngeal preservation strategies is still to be defined. There are some early promising studies, but the lack of validation and larger multicentric studies limit the value of the papers published in the literature and its application in clinical practice.

show abstract

Prognostic value of interim CT-based peritumoral and intratumoral radiomics in laryngeal and hypopharyngeal cancer patients undergoing definitive radiotherapy

Lin,

Yan,

Yap

et al. 2023

Radiotherapy and Oncology

View full text Add to dashboard Cite

Delta-volume radiomics of induction chemotherapy to predict outcome of subsequent chemoradiotherapy for locally advanced hypopharyngeal cancer

Cited by 3 publications

References 45 publications

Combination of clinical, radiomic, and “delta” radiomic features in survival prediction of metastatic gastroesophageal adenocarcinoma

Combination of clinical, radiomic, and “delta” radiomic features in survival prediction of metastatic gastroesophageal adenocarcinoma

The added value of radiomics in determining patient responsiveness to laryngeal preservation strategies

Prognostic value of interim CT-based peritumoral and intratumoral radiomics in laryngeal and hypopharyngeal cancer patients undergoing definitive radiotherapy

Contact Info

Product

Resources

About